A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
The purpose of the study is to collect real-life data during the early post-market authorization approval period in Germany.

The study aims at describing the outcomes, patient characteristics, safety profile, treatment patterns and patient-reported Quality of Life of first-line treatment with nivolumab plus ipilimumab in combination with two cycles of chemo therapy in participants with confirmed stage IV Non-Small Cell Lung Cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
Overall survival (OS), Up to 5 years
Overall Survival (OS) according to subgroups of interest, Up to 5 years|Progression-free survival (PFS), Up to 5 years|Duration of treatment, Up to 5 years|Distribution of socio-demographic characteristics of participants, Age, Sex, Ethnicity, Height, Weight and BMI, At Baseline|Distribution of clinical characteristics of participants, Histology subtype, Tumor stage, Location or primary tumor and Location of metastases, At Baseline|Description of participant-reported outcomes (PROs) of participants using European Quality of Life-5 Dimensions (EQ-5D) questionnaires, Up to 5 years|Description of participant-reported outcomes (PROs) of participants using Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), Up to 5 years|Management of AEs: Treatment of AEs, Up to 5 years|Management of AEs: Date of occurrence of AE, Up to 5 years|Management of AEs: Start of treatment, Up to 5 years|Treatment Patterns: Previous therapies, Up to 5 years|Treatment Patterns: Subsequent therapies, Up to 5 years|Treatment patterns: Concomitant medication, Up to 5 years|Treatment patterns : Management of treatment-related adverse events [AEs], previous and subsequent therapies, Up to 5 years
The purpose of the study is to collect real-life data during the early post-market authorization approval period in Germany.

The study aims at describing the outcomes, patient characteristics, safety profile, treatment patterns and patient-reported Quality of Life of first-line treatment with nivolumab plus ipilimumab in combination with two cycles of chemo therapy in participants with confirmed stage IV Non-Small Cell Lung Cancer (NSCLC).